Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy.

Next Previous
X
Search
Trial Profile

Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX-3379 (Primary) ; Cetuximab; Erlotinib; Trastuzumab; Vemurafenib
  • Indications Advanced breast cancer; Colon cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals

    • Most Recent Events

    • 21 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 06 Apr 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
    • 06 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 28 Apr 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top